We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
02 Nov 2020 - 06 Nov 2020
Virtual Venue
05 Nov 2020 - 07 Nov 2020

AI in Medical Imaging to Reach USD 1.5 Billion by 2024

By HospiMedica International staff writers
Posted on 23 Sep 2020
Print article
Illustration
Illustration
The global market for AI-based clinical applications for use in medical imaging is set to reach almost USD 1.5 billion by 2024 despite a slower-than-expected uptake of these products and the impact of the COVID-19 pandemic.

The market growth is projected to accelerate as the pandemic subsides and customer confidence in AI-based clinical solutions increases, with a peak annual growth rate of 44% forecast for 2022. These are the latest findings of Signify Research (Cranfield, UK), an independent supplier of market intelligence and consultancy to the global healthcare technology industry.

In 2019, 86% of the world market for AI-based clinical applications for medical imaging was accounted for by four clinical specialties (in order of market size): cardiology, neurology, breast, and pulmonology. Cardiology is forecasted to enjoy the largest revenue growth, followed by pulmonology, and these four clinical segments are projected to still account for more than 75% of the market in 2024. However, new product introductions of AI solutions for other clinical segments, most notably prostate and liver imaging, are on the rise.

Until now, the growth of the global market for AI-based clinical applications for use in medical imaging has been less rapid than anticipated by several industry experts due to several technical and commercial barriers, and a further set back dealt by the COVID-19 global pandemic. These barriers to market adoption, including the utility of AI in clinical practice, lack of clinical validation, challenges of workflow integration, and limited reimbursement, must be fully addressed before the use of AI in radiology becomes mainstream.

“The market is highly dynamic and continues to evolve at a rapid pace, said Dr. Sanjay Parekh. Senior Analyst at Signify Research. “There are frequent product launches, and the availability of regulatory approved products is accelerating. Since 2018, almost 60 AI-based clinical applications for medical imaging have received US-FDA approval, while a similar number of solutions have received CE Mark approval.”

Despite the many challenges of bringing medical imaging AI solutions to market, "radiology AI is here to stay," added Dr. Parekh. "From enhanced productivity and increased diagnostic accuracy, to more personalized treatment planning and improved clinical outcomes, AI will play a key role in enabling radiologists to meet the demands of their workload. The increasing volume of diagnostic imaging procedures, exacerbated by the current backlog of imaging exams due to national lockdowns, coupled with the shortage of radiologists in many countries, will undoubtedly further increase the need for AI in radiology."

Related Links:
Signify Research


Print article
Radcal
M.I ONE Co., Ltd

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.